BiotechTube
NEOK Bio

NEOK Bio

Cambridge, United States· Est.
neokbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $75M

Overview

NEOK Bio is a private, pre-clinical stage biotech pioneering next-generation bispecific antibody drug conjugates (ADCs) for oncology. The company leverages a proprietary platform and the antibody engineering capabilities of its strategic backer, ABL Bio, to develop dual-targeting ADCs designed for enhanced tumor selectivity and reduced toxicity. With a seasoned leadership team and a pipeline focused on validated targets, NEOK aims to address significant unmet needs in solid tumor cancers.

Oncology

Technology Platform

Next-generation bispecific antibody-drug conjugate (ADC) platform designed for dual-targeting to improve tumor selectivity, safety, and efficacy in solid tumors. Leverages antibody engineering from ABL Bio.

Funding History

1
Total raised:$75M
Venture$75M

Opportunities

The global ADC market is rapidly expanding, creating a significant opportunity for improved next-generation therapies.
NEOK's bispecific approach targets a key limitation of current ADCs (lack of selectivity), which could address unmet needs in large solid tumor indications and attract partnership or acquisition interest from larger oncology-focused pharma companies.

Risk Factors

The company faces high technical risk as its complex bispecific ADC platform is unproven in clinical development.
As a preclinical, private company, it is dependent on the continued financial and strategic support of its sole backer, ABL Bio, and operates in an intensely competitive landscape against well-funded rivals.

Competitive Landscape

NEOK competes in the crowded and fast-evolving next-generation ADC space against large pharmaceutical companies (e.g., AstraZeneca, Pfizer, Merck) and numerous biotechs, all developing novel ADC technologies including bispecifics, prodrugs, and new payloads. Differentiation will require demonstrating clear preclinical and clinical advantages over these established players.

More companies in Antibody-Drug Conjugates →More companies in United States →